FINCAD Launches Pioneering Python Toolkit for Valuation and Risk Analytics
FINCAD, the leading provider of enterprise solutions for derivative and fixed income portfolios, today announced innovative enhancements to FINCAD F3, an advanced valuation and risk analytics solution. A comprehensive Python toolkit has been added to F3, enabling traders, quants, portfolio managers and risk managers to rapidly generate custom analytics, applications and reports to drive better investment and risk decisions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181011005479/en/
FINCAD F3 Python Trade Script for a TARN (Photo: Business Wire)
Due to its versatility and ease of use, Python has achieved widespread adoption in finance, and has become the multi-purpose tool of choice for quantitative analysts and other financial technologists. However, while it is easy to start projects with Python, deploying them to production can be challenging, and teams often struggle with infrastructure issues such as data management, calculation scaling, version control, admin and security.
The F3 Python toolkit helps clients address this challenge by combining Python’s sophisticated capabilities, FINCAD’s industry-standard analytics library and the enterprise-class technology of F3 Platform, which automatically handles the infrastructure issues. The result is that portfolio managers, traders, and quants can maximize their productivity and focus on creating real business value without the heavy burden of enterprise infrastructure and software concerns. Common use cases cover a wide range, including strategy back-testing, structured product scripting, portfolio optimization, tailored hedging strategies, LDI portfolio construction, cash flow matching, custom pre-trade analytics, risk reports and real-time dashboards.
“Python enables clients to be incredibly productive and it has a rich ecosystem that is ideally suited to portfolio and risk analysis,” said James Church, VP of R&D at FINCAD. “The F3 Python toolkit goes far beyond a simple Python API, and brings together best-of-breed pricing and risk analytics, enterprise scalability, data management and UI tools so that teams can collaborate on ideas, then take them quickly and easily into production.”
The FINCAD F3 Python toolkit includes an F3 Python SDK, F3 Python MicroServices and F3 Python Trade Scripting which enable users to:
- Rapidly deliver custom analytics: Leverage Numpy, Scipy, pandas, Plotly and other standard Python libraries with the most up-to-date Python features to create custom analytics, such as portfolio optimizers, which can be integrated into other applications.
- Easily create custom applications and reports: Native integration with Jupyter Notebooks and Jupyter Lab, PyCharm, Visual Studio and Visual Studio Code, enable faster report and application development with familiar tools, without needing to learn a new development environment. Also included are tools for building rich, interactive UIs without being a developer; and it comes with a complete set of widgets for reporting, selecting books, trades and models, and for handling many types of financial inputs and outputs.
- Quickly model and script complex payoffs: Use Python’s concise, highly expressive syntax with F3 analytics and data. Complex modeling and scripting can be abstracted away or dealt with using data-driven approaches.
“With enterprise portfolio and risk systems, one size doesn’t fit all,” noted Bob Park, FINCAD President and CEO. “Every investment firm is unique, and their software should be flexible and able to adapt to their specific needs, workflows and requirements. With FINCAD F3, firms don’t have to settle for software that is ‘good enough’, nor do they have to make compromises. They get the unparalleled combination of powerful out-of-the-box functionality and the flexibility for unlimited customization using versatile tools such as Python.”
FINCAD is the leading provider of valuation and risk solutions for derivative and fixed income portfolios. An industry standard since 1990, our advanced analytics, flexible architecture and patented technology enable better investment and risk management decisions. We are committed to helping our clients solve their toughest challenges, without compromise. Clients include leading global asset managers, hedge funds, insurance companies, pension funds, banks and auditors. For more information, visit www.fincad.com.
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
AURAK Gains SACSCOC Accreditation15.12.2018 13:49 | Tiedote
The Southern Association of Colleges and Schools Commission on Colleges (SACSCOC) officially announced the accreditation of the American University of Ras Al Khaimah (AURAK) at its 2018 Annual Meeting which was held in New Orleans, Louisiana, in the United States of America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181215005017/en/ AURAK delegation during the SACSCOC conference in New Orleans” (Photo: AETOSWire) SACSCOC, the regional body for the accreditation of degree-granting higher education institutions in the Southern United States, has a membership of more than 800 institutions in the Southern states and other international sites approved by SACSCOC that award associate, baccalaureate, master’s, and/or doctoral degrees. SACSCOC also awards accreditation to other international institutions of higher education that satisfy all its requirements and demonstrate compliance with its accreditation standards. AURAK now
Lehman Brothers Treasury Announces Plans for Partial Wind-Down14.12.2018 20:41 | Tiedote
Lehman Brothers Treasury Co. B.V. in liquidation (“LBT”) today, through its U.S. counsel Kramer Levin Naftalis & Frankel LLP, announced that LBT is planning a final cash distribution to its creditors. Professional holders of eligible notes will have the option to retain their investment by electing to receive substitute notes of one (or a few) series. Such election shall take place through a solicitation process. As a consequence, LBT will be able to reduce the number of series of notes outstanding from more than 3,700 to one or a few. Noteholders electing to receive substitute notes will be afforded the same economic entitlement to distributions received by LBT from Lehman Brothers Holdings Inc. (“LBHI”) through the substitute notes. The substitute notes will be denominated in U.S. dollars and future distributions will be made in U.S. dollars only. Noteholders who are not professional investors, or hold notes that are not eligible for substitution, or do not elect to receive substitut
Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD14.12.2018 20:00 | Tiedote
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the extension of the marketing authorization of ADCETRIS (brentuximab vedotin) and recommended its approval in combination with AVD in adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma. ADCETRIS is an antibody-drug conjugate (ADC) directed at CD30, a defining marker of Hodgkin lymphoma. ADCETRIS is currently not approved as a therapy for previously untreated Hodgkin lymphoma in Europe. “For a large number of previously untreated Hodgkin lymphoma patients diagnosed with Stage IV disease, progression will occur with current treatments, highlighting a true unmet need in this population,” said Anna Sureda, M.D., Ph.D., Head of the Hematology Department and Hematopoietic Stem Cell Transplant Programme, Institut Català d'Oncologia - Hospital Duran i Reynals. “In the ECHELON-1 cl
Diamond CBD, POTN Subsidiary, Enters the $46 Billion Coffee Market With the Release of Premium Line of CBD-Infused Coffee & Tea K-Kup Capsules14.12.2018 18:42 | Tiedote
Diamond CBD Inc., wholly owned subsidiary of PotNetwork Holdings, Inc. (OTC Pink: POTN), a leader in hemp extraction and innovative CBD products for the wellness market, enters the Coffee segment, an industry expected to reach revenues of $46 Billion in 2018. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181214005308/en/ Experience a cup of Chill (Photo: Business Wire) Produced in accordance with a universal K-Cup design, these pods fit in almost all modern single cup coffee makers, making it an easily integrated enhancement to any environment, delivering 25mgs of CBD in a tasty favorite beverage at less than $5 per cup. This new line of premium Chill Coffee Capsules was recently added to the Company’s broad range of cannabinoid and natural hemp products. Each box comes with 4 individual capsules in original chill coffee, decaf chill coffee, chill black tea, and chill green tea flavors. The unit price for each box is $10.00
Henley & Partners Enlarges Executive Committee to Manage Expansion and Growth14.12.2018 17:00 | Tiedote
Residence- and citizenship-by-investment programs have firmly established themselves over the past few years as the new frontier in terms of freedom, flexibility, and future-readiness, both for the countries issuing these programs and for the individual investors participating in them. The societal and economic value these programs generate is undisputed. The investment migration industry as a whole is currently grossing roughly USD 18 billion per year, with an expectation that it will hit the USD 20 billion mark very soon. Foreign direct investment (FDI) is now considered the lifeblood of economic growth for many developing and recovering smaller countries around the world. As such, the number of investment migration programs has been increasing rapidly, from just a handful of programs in the 1980s and 1990s to over 100 countries that now have investment migration provisions in their laws. There are more than 60 active programs today, with Moldova and Montenegro — both fast-growing Eu
Vargatef® plus docetaxel could be an option after failure of immunotherapy in lung cancer14.12.2018 12:07 | Tiedote
Boehringer Ingelheim announced today the first interim results of VARGADO, an ongoing non-interventional study in routine clinical practice in Germany evaluating the efficacy and safety of Vargatef® (nintedanib) and docetaxel in patients with stage III/IV locally advanced or metastatic non-small cell lung cancer (NSCLC) of adenocarcinoma histology. The study consists of three cohorts, two of which allow for prior treatment with immune checkpoint inhibitors (ICIs) either in combination with chemotherapy in the first-line or as monotherapy in the second-line of treatment. The interim results from Cohort B (first-line chemotherapy, second-line immune checkpoint inhibitors, third-line Vargatef® plus docetaxel) were presented today at ESMO Immuno-Oncology Congress 2018 in Geneva.1 Despite a limited sample size, the VARGADO study adds to the body of evidence for nintedanib in lung adenocarcinoma following pre-treatment with chemotherapy and ICIs.1,3 The addition of nintedanib to docetaxel ha
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme